Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
| ▸ | WNT3A | P56704 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13637169 | 0.80 | RAB9A (0.44) | DHODHMEN1POLBMAPTKMT2A | |
| SCHEMBL11828359 | 0.78 | EP300 (0.39) | DHODHHDAC4EP300WNT3A | |
| SCHEMBL10260862 | 0.77 | CYP1A2 (0.50) | XDHDHODHMEN1POLBKMT2A | |
| SCHEMBL6215593 | 0.77 | MKNK1 (0.50) | DHODHHDAC4EP300WNT3A | |
| SCHEMBL3118227 | 0.77 | HDAC4 (0.40) | DHODHHDAC4EP300WNT3A | |
| SCHEMBL6852546 | 0.77 | WNT3A (0.42) | DHODHHDAC4EP300WNT3A | |
| SCHEMBL3118237 | 0.77 | CYP2A6 (0.50) | DHODHHDAC4EP300WNT3A | |
| SCHEMBL25868356 | 0.75 | CYP1A2 (0.60) | DHODHHDAC4EP300 | |
| SCHEMBL31370434 | 0.75 | CYP1A2 (0.60) | DHODHHDAC4EP300 | |
| SCHEMBL6876121 | 0.74 | AOC3 (0.50) | DHODHHDAC4EP300WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | XDH 3375/4885DHODH 1413/4885MEN1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.